Switch from enfuvirtide to raltegravir in patients with undetectable viral load: Efficacy and safety at 24 weeks in a montreal cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 3, 2009, Pages 362-364

  Talbot, Annie ^a,b,c   MacHouf, Nima ^d   Thomas, Réjean ^d   Marcotte, Suzanne ^a   Therrien, Rachel ^a   Lessard, Bernard ^a,b   Dufresne, Serge ^a,b   Lalonde, Richard ^e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Clinique du Quartier Latin   (Canada)

^c STANFORD UNIVERSITY   (United States)

^d Clinique l'Actuel   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

ADULT; CANADA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LETTER; MALE; PRIORITY JOURNAL; VIRUS LOAD; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

ADULT; CANADA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PYRROLIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67651037343     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181aa1398     Document Type: Letter

References (7)

1. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N EnglJMed. 2003;348:2175-2185.
2. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
3. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. 2005;40:413-421.
4. Cooper DA, Gatell J, Rockstroh J, et al. 48-week results from BENCHMRK-1, a Phase III study of raltegravir in patients failing antiretroviral therapy with triple-class resistant HIV-1. presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 788.
5. Steigbigel R, Kumar P, Eron J, et al. 48-week results from BENCHMRK-2, a Phase III study of raltegravir in patients failing antiretroviral therapy with triple-class resistant HIV-1. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 789.
6. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial. Lancet. 2007;369:1261-1269.
7. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically sup-pressive regimen. AIDS. 2008;22:1224-1226.